Med Tech Earnings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Duraheart progress: German clinical trials of Terumo's destination therapy left-ventricular assist system will conclude by mid-2005, with European CE mark anticipated in 2006, the Japanese company reports during a July 28 earnings call. So far, nine patients have been implanted with the device, which Terumo calls "the world's first LVAS with a magnetically suspended centrifugal pump." In the U.S., Ann Arbor, Mich.-based Terumo Heart, Inc. is handling R&D and regulatory activities....Anaconda swoops for AAA market: Terumo expects a CE mark for its abdominal aortic aneurysm endograft in 2005, the firm notes, adding that four patients have received the implant in U.S. trials. Terumo targets 2007 for a U.S. launch of the AAA endograft - acquired along with Centerpulse unit Vascutek in 2002...
You may also be interested in...
Zimmer Integration Effort “Ahead Of Schedule,” Will Cost $79 Mil. In 2004
Zimmer hopes to further differentiate its total knee replacement offerings with the formal launch of its MIS Quad-Sparing minimally-invasive implant procedure at the American Academy of Orthopedic Surgeons meeting March 10-14 in San Francisco
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.